Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
27 févr. 2024 06h00 HE
|
Esperion Therapeutics, Inc.
– FY23 U.S. Net Product Revenue Grew 40% Y/Y to $78.3 Million; FY23 Total Revenue Grew 54% Y/Y to $116.3 Million – – Q4 U.S. Net Product Revenue Grew 39% Y/Y to $20.8 Million; Q4 Total Revenue Grew...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16 févr. 2024 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on February 13, 2024, the Company granted 66 new employees 204,900 restricted stock units (RSUs)...
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
13 févr. 2024 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2023 financial results before the market opens on Tuesday,...
RFK, Esperion Therapeutics Announce 2024 Promotional Schedule
01 févr. 2024 14h00 HE
|
Esperion Therapeutics, Inc.
CONCORD, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- RFK Racing and Esperion Therapeutics have announced the promotional schedule for the 2024 season, highlighted by a four-race slate, and numerous...
Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
23 janv. 2024 16h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today the closing of its previously announced underwritten...
Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock
18 janv. 2024 21h15 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today the pricing of its previously announced underwritten...
Esperion Announces Proposed Public Offering of Common Stock
18 janv. 2024 16h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today that it has commenced an underwritten public offering...
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
03 janv. 2024 07h00 HE
|
Esperion Therapeutics, Inc.
– Near term payment to Esperion of $100 million plus $25 million in calendar quarter following EMA’s expected decision on Type II(a) variation approval of NILEMDO® (bempedoic acid) Tablet and...
Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference
18 déc. 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference. Sheldon Koenig, President and CEO,...
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
13 déc. 2023 16h00 HE
|
Esperion Therapeutics, Inc.
– Updated Label Adds Primary Hyperlipidemia, Removes Maximally Tolerated Statin Requirement, Removes Limitation of Use – – Cardiovascular (CV) Risk Reduction Labels Remain on Track: in U.S. with...